The use of tranexamic acid (TXA) has markedly increased since the results of the CRASH-II trial were published. In addition to its use in trauma, TXA has been evaluated and used in numerous other conditions, including post-partum hemorrhage and epistaxis. Recently, the HALT-IT Trial was published online in the Lancet, which evaluated the use of TXA in patients with acute gastrointestinal bleeding. In this podcast we discuss the HALT-IT Trial and its implications for clinical practice.
You can get CME credit for this episode here!Click here for CME Account Creation Instructions
Approximately 75% of patients older than 65 years of age are seen in an ED within 6 months of their death. While palliative care...
Peds EM superstars Mimi Lu and Barrie Bostick join CCPEM to review the latest clinical guidelines on hemodynamic support of pediatric and neonatal septic...
Transcatheter aortic valve replacement is now more common than open surgical replacement and may be associated with lower mortality. Given the significant increase in...
